NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market on Monday that its third-quarter revenues increased 42 percent, driven by a sharp uptick in molecular diagnostics sales.

The Salt Lake City-based firm generated revenues of $87.5 million for the three-month period ended Mar. 31, compared to $61.8 million for the first quarter of 2008. Its molecular diagnostics sales were $86.5 million, up from $59 million in Q1 2008, while its research and other revenue fell to just under $1 million from $2.7 million the year before.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.